Literature DB >> 7505115

Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate.

M Anafi1, A Gazit, A Zehavi, Y Ben-Neriah, A Levitzki.   

Abstract

We report on the potency of two Tyrphostin tyrosine kinase blockers, AG 1112 and AG 568, to inhibit p210bcr-abl tyrosine kinase activity in K562 cells, concomitant with the induction of erythroid differentiation. AG 568 and especially AG 1112 represent a specific group of nontoxic protein tyrosine kinase blockers among more than 1,400 tested. These compounds possess therapeutic potential for purging Philadelphia chromosome-positive cells in preparation for autologous bone marrow transplantation in chronic myelogenous leukemia.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 7505115

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  16 in total

1.  BCR/ABL inhibition by an escort/phosphatase fusion protein.

Authors:  Y M Lim; S Wong; G Lau; O N Witte; J Colicelli
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

Review 2.  Treatment for chronic myelogenous leukemia: the long road to imatinib.

Authors:  Tony Hunter
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

Review 3.  Following the cytokine signaling pathway to leukemogenesis: a chronology.

Authors:  Kendall A Smith; James D Griffin
Journal:  J Clin Invest       Date:  2008-11       Impact factor: 14.808

4.  Development of a protease-resistant reporter to quantify BCR-ABL activity in intact cells.

Authors:  Angela Proctor; Imola G Zigoneanu; Qunzhao Wang; Christopher E Sims; David S Lawrence; Nancy L Allbritton
Journal:  Analyst       Date:  2016-10-17       Impact factor: 4.616

Review 5.  STI571: a gene product-targeted therapy for leukemia.

Authors:  M J Mauro; B J Druker
Journal:  Curr Oncol Rep       Date:  2001-05       Impact factor: 5.075

6.  My journey from tyrosine phosphorylation inhibitors to targeted immune therapy as strategies to combat cancer.

Authors:  Alexander Levitzki; Shoshana Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2019-05-10       Impact factor: 11.205

7.  Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate.

Authors:  T Era; O N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

8.  Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation.

Authors:  M L Gishizky; D Cortez; A M Pendergast
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

9.  Protein tyrosine phosphatase PTP1B suppresses p210 bcr-abl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells.

Authors:  K R LaMontagne; G Hannon; N K Tonks
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

Review 10.  Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.

Authors:  Michael W N Deininger
Journal:  J Cancer Res Clin Oncol       Date:  2003-11-07       Impact factor: 4.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.